TOP HEADLINES

Featured Story

Virginia lab zeroes in on a possible key target for male contraceptive

John Herr's lab at the University of Virginia made the cover of the scientific journal Biology of Reproduction with new work on finding a male contraceptive.

Investigators say they've designed a new-and-improved antibiotic

Francesc Rabanal, a professor in the Department of Organic Chemistry of the University of Barcelona, has spearheaded work on a new prototype compound that he says shows clear activity against both Gram-negative and Gram-positive bacteria.

Team spotlights new evidence that Parkinson's starts in the gut

Following up on what's billed as the largest epidemiological study ever done on Parkinson's disease, a group of scientists at Aarhus University in Denmark say they have determined that the neurological ailment begins in the gut and then spreads through the body by way of the vagus nerve.

Purdue group finds Achilles' heel for MERS

Researchers at Purdue University say they have identified molecules that can shut down a key enzyme needed by the Middle East respiratory syndrome, or MERS, virus.

New study will test feds' support for anti-aging drug research

Investigators will be making the trek to Washington later this month to make the case for a new study that will explore the impact that metformin has on aging. And in the process, they'll be testing regulators' attitudes about an emerging field in drug development.

MORE NEWS

From Our Sister Sites

FierceBiotech

Celgene is paying about $1 billion to move to the front of the hectic race to build new CAR-T cancer therapies. The Big Biotech is shelling out $150 million upfront and paying $93 a share--a huge premium--to snap up 9.1 million shares of Juno Therapeutics, inking a collaboration to develop and commercialize new oncology therapies.

FiercePharma Manufacturing

Several years ago, GlaxoSmithKline committed $50 million to set up an antibiotics facility in Singapore to do continuous processing, a radically different manufacturing approach that has a much smaller footprint, and so much lower operating costs and less environmental impact, than traditional batch processing. The drugmaker now says it is ready to embark on a £38 million expansion there.